losartan has been researched along with Atrophy in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease." | 9.41 | Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. ( Barnes, J; Ben-Shlomo, Y; Blair, PS; Clegg, SL; Coulthard, E; Fox, NC; Howden, B; Jarutyte, L; Kehoe, PG; Lane, JA; Malone, IB; Mutsaerts, HJ; Nielsen, C; Passmore, P; Sudre, CH; Taylor, J; Thai, NJ; Thomas, DL; Turner, N; Wilkinson, I; Wilson, A, 2021) |
| "We divided 2-month-old male Sprague-Dawley rats into 4 groups, namely group 1-control, group 2-hyperoxaluria, group 3-hyperoxaluria plus losartan and group 4-losartan." | 7.71 | Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. ( Angerosa, M; De Cavanaugh, EM; Ferder, L; Inserra, F; Stella, I; Toblli, JE, 2002) |
| "12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease." | 5.41 | Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. ( Barnes, J; Ben-Shlomo, Y; Blair, PS; Clegg, SL; Coulthard, E; Fox, NC; Howden, B; Jarutyte, L; Kehoe, PG; Lane, JA; Malone, IB; Mutsaerts, HJ; Nielsen, C; Passmore, P; Sudre, CH; Taylor, J; Thai, NJ; Thomas, DL; Turner, N; Wilkinson, I; Wilson, A, 2021) |
| "Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin." | 5.36 | Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010) |
| "We divided 2-month-old male Sprague-Dawley rats into 4 groups, namely group 1-control, group 2-hyperoxaluria, group 3-hyperoxaluria plus losartan and group 4-losartan." | 3.71 | Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. ( Angerosa, M; De Cavanaugh, EM; Ferder, L; Inserra, F; Stella, I; Toblli, JE, 2002) |
| "Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin." | 1.36 | Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kehoe, PG | 2 |
| Turner, N | 1 |
| Howden, B | 2 |
| Jarutyte, L | 1 |
| Clegg, SL | 1 |
| Malone, IB | 2 |
| Barnes, J | 1 |
| Nielsen, C | 1 |
| Sudre, CH | 1 |
| Wilson, A | 1 |
| Thai, NJ | 1 |
| Blair, PS | 2 |
| Coulthard, E | 2 |
| Lane, JA | 1 |
| Passmore, P | 1 |
| Taylor, J | 1 |
| Mutsaerts, HJ | 1 |
| Thomas, DL | 2 |
| Fox, NC | 2 |
| Wilkinson, I | 1 |
| Ben-Shlomo, Y | 2 |
| Horwood, J | 1 |
| Clement, C | 1 |
| Selman, LE | 1 |
| Baber, H | 1 |
| Lane, A | 1 |
| Passmore, AP | 1 |
| Wilkinson, IB | 1 |
| Ulmasov, B | 1 |
| Xu, Z | 1 |
| Talkad, V | 1 |
| Oshima, K | 1 |
| Neuschwander-Tetri, BA | 1 |
| Toblli, JE | 1 |
| Ferder, L | 1 |
| Stella, I | 1 |
| De Cavanaugh, EM | 1 |
| Angerosa, M | 1 |
| Inserra, F | 1 |
2 trials available for losartan and Atrophy
| Article | Year |
|---|---|
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Alzheimer Disease; Atrophy; Brain; Double-Blind Method; Humans; Losartan; Middle Aged; State Medicin | 2021 |
The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.
Topics: Activities of Daily Living; Alzheimer Disease; Antihypertensive Agents; Atrophy; Blood Pressure Moni | 2018 |
2 other studies available for losartan and Atrophy
| Article | Year |
|---|---|
Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse.
Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrophy; Ceruletide; Colla | 2010 |
Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria.
Topics: Angiotensin Receptor Antagonists; Animals; Atrophy; Fibrosis; Hyperoxaluria; Kidney Tubules; Losarta | 2002 |